☆ 4.6 Article

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

BLOOD ADVANCES (2023)

Related references

Note: Only part of the references are listed.

Review Pathology

Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma

Rebecca L. King et al.

Summary: This article reviews the discussions of the 2022 International Consensus Classification for lymphoid malignancies and provides detailed interpretations of the diagnostic criteria for Burkitt lymphoma and high-grade B-cell lymphomas. The separation of high-grade B-cell lymphomas with MYC and BCL2 rearrangements and MYC and BCL6 rearrangements is discussed, along with the FISH strategies for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

VIRCHOWS ARCHIV (2023)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Herve Tilly et al.

Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Hematology

Defining and treating high-grade B-cell lymphoma, NOS

Adam J. Olszewski et al.

Summary: High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes rare and heterogeneous tumors that cannot be classified as other well-defined lymphoma subtypes. Improved molecular diagnostics are needed to improve outcomes and treatment for patients.

BLOOD (2022)

Add to Collection

Review Hematology

CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights

Alaa Ali et al.

Summary: Significant progress has been made in identifying novel therapies for B-cell lymphomas, particularly in targeting CD19 antigen with autologous-derived CAR cells, which has shown high efficacy in patients with relapsed/refractory lymphomas. The biological underpinnings and overlap with other lymphomas are still being intensely investigated.

BLOOD (2022)

Add to Collection

Article Hematology

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo et al.

Summary: Since 1994, the classification of lymphoid neoplasms has been continuously updated through international efforts, with recent progress driven by genomic studies. This proposal presents the International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors, which has refined diagnostic criteria and incorporated new insights from genomics.

BLOOD (2022)

Add to Collection

Article Hematology

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

Anna Dodero et al.

Summary: This study reports the efficacy of DA-EPOCH-R treatment in patients with DLBCL, including DEL and DH/TH. The study found that TP53 mutations have a negative impact on prognosis, while systemic CNS prophylaxis can improve patient survival.

HAEMATOLOGICA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu et al.

Summary: In a phase 2 trial, axicabtagene ciloleucel demonstrated high complete response rate and manageable safety profile as first-line treatment for high-risk large B-cell lymphoma.

NATURE MEDICINE (2022)

Add to Collection

Article Hematology

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma

Andres J. M. Ferreri et al.

Summary: The CARMEN regimen has shown efficacy in treating lymphomas with MYC rearrangement, with promising outcomes, even in HIV-positive patients.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL

Shaoying Li et al.

Summary: This study investigated the clinicopathologic and genetic features of 136 HGBL-NOS patients compared to DLBCL/HGBL-DH and DLBCL patients. The study found that HGBL-NOS patients had similar clinical features to DLBCL/HGBL-DH patients. However, their overall survival was inferior to DLBCL patients.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar et al.

LANCET (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Add to Collection

Meeting Abstract Hematology

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Narendranath Epperla et al.

BLOOD (2022)

Add to Collection

Article Hematology

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A. Ollila et al.

BLOOD (2021)

Add to Collection

Article Oncology

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

Joo Y. Song et al.

Summary: Detailed genomic analysis of 87 cases of GCB DLBCL identified four distinct biological subgroups with different survivals. A practical schema was proposed to risk-stratify patients with GCB DLBCL and to identify high-risk patients for new and innovative therapies.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Wyndham H. Wilson et al.

Summary: In younger patients with non-GCB DLBCL, the addition of ibrutinib to R-CHOP chemotherapy improves survival rates, particularly in patients with MCD and N1 subtypes. This study provides mechanistic understanding of the benefit of ibrutinib in this patient population.

CANCER CELL (2021)

Add to Collection

Article Oncology

Burkitt Lymphoma International Prognostic Index

Adam J. Olszewski et al.

Summary: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Pathology

The Burkitt-like immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS

Katrin S. Huettl et al.

Summary: Burkitt lymphoma is characterized by a specific immunophenotype and genetic features, typically requiring intensified chemotherapy. Despite morphologic overlap with other high-grade B cell lymphomas, the combination of CD10+, BCL6+, BCL2- and MYCR positive immunophenotype is relatively rare.

VIRCHOWS ARCHIV (2021)

Add to Collection

Article Education, Scientific Disciplines

Double-hit lymphoma: optimizing therapy

Kieron Dunleavy

Summary: Aggressive B-cell lymphoma is a heterogeneous entity, with high-grade B-cell lymphoma (HGBL) and HGBL-not otherwise specified differing from DLBCL and possibly requiring distinct treatment approaches. Studies suggest poor outcomes with standard therapy for HGBL patients, indicating the potential benefit of dose-intense treatment regimens.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)

Add to Collection

Article Hematology

BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDY

S Leppä et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Manman Deng et al.

Summary: The study indicates that DLBCL/HGBCL patients with MYC/TP53 dual abnormalities exhibit poor clinical outcomes and high-grade morphology, suggesting the need for additional targeted therapies.

MOLECULAR CANCER RESEARCH (2021)

Add to Collection

Article Hematology

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens et al.

Summary: The study found that patients with Burkitt lymphoma who received rituximab treatment had higher survival rates, while factors such as age, ECOG performance status, lactate dehydrogenase levels, and central nervous system involvement could affect patient survival.

BLOOD (2021)

Add to Collection

Letter Oncology

Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma

Dominic P. Decker et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Hematology

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial

Martine E. D. Chamuleau et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial

A. K. McMillan et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Hematology

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart E. Lacy et al.

BLOOD (2020)

Add to Collection

Article Oncology

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

George W. Wright et al.

CANCER CELL (2020)

Add to Collection

Article Oncology

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Mark Roschewski et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases

Jiayin Li et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Add to Collection

Article Oncology

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium

Andreas Rosenwald et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy et al.

NATURE MEDICINE (2018)

Add to Collection

Article Hematology

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy et al.

LANCET HAEMATOLOGY (2018)

Add to Collection

Article Oncology

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Daniel J. Landsburg et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Anupama Reddy et al.

CELL (2017)

Add to Collection

Review Hematology

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Steven H. Swerdlow et al.

BLOOD (2016)

Add to Collection

Article Hematology

Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma

Ken-ichi Miyamoto et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)

Add to Collection

Article Pathology

Clinical Significance of MYC Expression and/or High-grade Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas A SWOG S9704 Correlative Study

James R. Cook et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)

Add to Collection

Article Hematology

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich et al.

BLOOD (2014)

Add to Collection

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Hematology

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases

Anamarija M. Perry et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Article Hematology

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu-Monette et al.

BLOOD (2012)

Add to Collection

Article Mathematical & Computational Biology

Multiple imputation using chained equations: Issues and guidance for practice

Ian R. White et al.

STATISTICS IN MEDICINE (2011)

Add to Collection

Article Hematology

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Graham M. Mead et al.

BLOOD (2008)

Add to Collection

Article Oncology

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

DA Thomas et al.

CANCER (2006)

Add to Collection

Article Hematology

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

CP Hans et al.

BLOOD (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.